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CetuximabRAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor
receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often
result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS
exon 2 (codon 12/13) are an established predictor of lack of response to the anti-EGFR monoclonal anti-
bodies cetuximab and panitumumab in patients with metastatic colorectal cancer (mCRC), and have been
used routinely in clinical practice to identify patients unlikely to derive beneﬁt from these therapies.
However, a meaningful proportion of patients with mCRC have tumors bearing other mutations in RAS
genes. Recent studies have demonstrated that evaluation of an extended panel of RASmutations—includ-
ing mutations in KRAS exon 2, 3, and 4 and NRAS exons 2, 3, and 4—can better deﬁne the patient popu-
lation that is unlikely to beneﬁt from anti-EGFR therapy, with concomitant improvements in outcomes in
the more highly selected RAS wild-type group. This discovery has changed the practice of oncology and
has the potential to spare patients from exposure to ineffective therapy. In the near future, it is important
for the oncology community to validate extended RAS analysis assays and make certain that patients who
are candidates for anti-EGFR therapy undergo appropriate testing and treatment.
 2015 Published by Elsevier Ltd.Introduction
The epidermal growth factor receptor (EGFR), a transmembrane
receptor tyrosine kinase overexpressed in a number of human can-
cers, has become an important therapeutic target in colorectal can-
cer [1]. The EGFR signaling pathway is involved in a range of
cellular functions, including regulation of cell proliferation, migra-
tion, differentiation, and survival [1]. There is strong evidence that
activation of the EGFR signaling pathway has a critical role in the
malignant transformation of normal cells, and overexpression
and activation of members of the EGFR family of membrane recep-
tors is characteristic of a number of human cancers, including
colorectal cancer [2]. Panitumumab and cetuximab are anti-EGFRmonoclonal antibodies that have been shown to improve outcomes
in patients with metastatic colorectal cancer (mCRC) [3–6].
Panitumumab, a recombinant, fully human immunoglobulin G2
anti-EGFR monoclonal antibody [7], and cetuximab, a recombinant
human/mouse chimeric immunoglobulin G1 anti-EGFR mono-
clonal antibody [8], both have a high afﬁnity for the extracellular
domain of EGFR, competitively inhibiting the binding of EGFR
ligands leading to inhibition of EGFR-mediated signaling, with
resulting antitumor activity [7,8]. The activity of these agents in
mCRC was ﬁrst demonstrated in phase 3 studies in patients with
chemotherapy-refractory disease [4,6]. They have subsequently
been shown to have similar efﬁcacy to one another in mCRC: an
open-label, phase 3, randomized, noninferiority study (ASPECCT)
in patients with chemotherapy-refractory wild-type KRAS exon 2
mCRC showed that panitumumab was noninferior to cetuximab,
with similar hazard ratios for OS and PFS [9].
Initially, cetuximab and panitumumab were evaluated in unse-
lected mCRC patients. Subsequent investigation has evaluated and
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monoclonal antibodies, in particular mutations in the RAS protein
family. Use of these biomarkers help identify patients most likely
to beneﬁt from treatment with anti-EGFR monoclonal antibodies
and spare potential treatment-related toxicity in patients who
are unlikely to respond. This review discusses the biology of RAS
proteins and the clinical utility of RAS mutations as predictors of
response and summarizes analyses of phase 3 studies that have
evaluated the predictive value of RAS mutations in patients with
mCRC.Biology of RAS proteins
Members of the RAS family of small guanine nucleotide-binding
proteins play an important role in intracellular signaling pathways
regulated by a range of cell surface receptors, including EGFR
[10,11]. By acting as guanosine diphosphate/guanosine triphos-
phate (GTP)-regulated signal switch molecules, the RAS proteins
control a diverse range of cellular responses, including prolifera-
tion, differentiation, and survival [11,12]. The three RAS isoforms
(KRAS, NRAS, and HRAS) are highly homologous to one another,
sharing a common identity over 80% to 90% of the coding sequence
[11,12]. The amino-terminal portion of the proteins consists of
a hypervariable region, allowing for posttranslational protein
modiﬁcations resulting in signiﬁcant divergence in trafﬁcking
and activity [11,12].
Ligand binding to the EGFR receptor with subsequent receptor
dimerization activates a number of downstream signaling path-
ways. Among the best characterized of the RAS effector pathways
is the mitogen-activated protein kinase (MAPK) cascade, in which
the serine/threonine kinase BRAF plays a key regulatory role [12].
Other RAS signaling pathways include the phosphatase and tensin
homolog (PTEN)/phosphatidyl-inositol 3-kinase (PI3K)/AKT path-
way and the signal transducer and activator of transcription
(STAT) pathway, which induces transcriptional regulation of cell
division, differentiation, migration, adhesion, and apoptosis
[11,12]. Activating mutations in RAS proteins (occurring at speciﬁc
loci in exons 2, 3, and 4) inhibit GTPase activity, modulate the gua-
nine nucleotide exchange rate, or desensitize their activation by
GTPase-activating proteins, resulting in constitutive activation of
RAS downstream effector pathways and imparting resistance to
inhibition of EGFR and other cell surface receptor kinases (Fig. 1)
[12–14]. Such dysregulation of the EGFR signaling pathway can
stimulate tumor growth, prolong tumor survival, and advance
the spread of metastatic disease [15]. In preclinical models of
mCRC, mutations in KRAS and NRAS have been shown to beFig. 1. Role of KRAS mutations in oncogenic activation and inactivation of normal
RAS signaling pathways. GAP = guanosine triphosphatase-activating proteins;
GDP = guanosine diphosphate; GEF = guanine exchange factors; GTP = guanosine
triphosphate. Adapted with permission from van Krieken JH, Jung A, Kirchner T,
et al. KRAS mutation testing for predicting response to anti-EGFR therapy for
colorectal carcinoma: proposal for a European quality assurance program. Virchows
Arch. 2008;453(5):417–431.constitutively activating, and are associated with an oncogenic
phenotype (with differing characteristics depending on the speciﬁc
mutation present) [16]. Activating mutations have also been
described in other RAS pathway effectors (eg, BRAF), and these play
a role in mCRC tumor development and progression [17].
Activating mutations in KRAS are common in pancreatic cancer,
non–small-cell lung cancer, and of particular relevance to this
review, colorectal cancer [10]. Overall, mutations in KRAS may
account for up to 85% of RASmutations, whereas activating muta-
tions in NRAS and HRAS are less common, representing 15% and
less than 1%, respectively [10,11]. Amino acid substitutions at
codons 12 and 13 in exon 2 are responsible for most mutations
in KRAS (88% of the recurrent mutations across all tumor types),
with the remainder present in exon 3 (codons 59, 61) and exon 4
(codons 117 and 146). In contrast, the most frequently occurring
recurrent mutations in NRAS and HRAS are seen in codon 61 of exon
3 [10,18].
Mutations in KRAS exon 2 as a biomarker
It was hypothesized that triggering of EGFR-independent intra-
cellular signal transduction activation of the RAS pathway by KRAS
exon 2 mutations could impair response to anti-EGFR monoclonal
antibodies in colorectal cancer [19,20]. Evidence supporting the
hypothesis that mutations in KRAS exon 2 (codons 12 and 13) were
associated with lack of response was provided by retrospective
analyses of the pivotal phase 3 trials of single-agent panitumumab
and cetuximab in patients with chemotherapy refractory disease
[3,5]. These phase 3 studies had enrolled patients with
chemotherapy-refractory disease without biomarker selection.
Both cetuximab and panitumumab were shown to improve
progression-free survival (PFS) compared with best supportive care
(BSC) alone [4,6]. In the panitumumab study [6], the hazard
ratio for PFS was 0.54 (95% CI, 0.44–0.66; P < 0.0001) whereas
in the cetuximab study [4], the hazard ratio for PFS was 0.68
(95% CI, 0.57–0.80; P < 0.001). Cetuximab also improved median
overall survival (OS; hazard ratio, 0.77; 0.64–0.92; P = 0.005).
Although a signiﬁcant improvement in OS was not shown for
panitumumab, the crossover of 76% of BSC patients to
panitumumab (which was allowed per the study protocol) likely
confounded the evaluation of OS; crossover was not allowed in
the cetuximab study.
Subsequent analyses of these two phase 3 studies evaluated
outcomes when patients were stratiﬁed by KRAS exon 2 mutation
status. In both analyses, the seven most frequently occurring muta-
tions in KRAS codons 12 and 13 (ie, exon 2) were evaluated using
allele-speciﬁc PCR and were found to be predictive of lack of
response to anti-EGFR monoclonal antibody monotherapy [3–6].
In the panitumumab study, in which KRAS status was ascertained
for 92% of patients, median PFS was improved by the addition of
panitumumab to BSC compared with BSC alone in patients with
wild-type KRAS exon 2 (12.3 versus 7.3 weeks, respectively; hazard
ratio, 0.45; 95% CI, 0.34–0.59), but not in patients with mutant
KRAS (7.4 versus 7.3 weeks, respectively; hazard ratio, 0.99; 95%
CI, 0.73–1.36) [3]. The quantitative interaction test for the relative
treatment effect between the KRAS wild-type and mutant groups
on PFS was P < 0.0001. Among patients in the KRAS wild-type
group, the ORR was 17% for those receiving panitumumab and
0% for those receiving BSC. No patient with mutant KRAS had an
objective response. Further analysis showed that the magnitude
of the relative treatment effect of panitumumab on PFS was greater
for the wild-type KRAS group (P < 0.0001); consistent results were
obtained for propensity-score adjusted hazard ratios.
In the cetuximab study (KRAS ascertainment, 69%), 12.8% of
patients with wild-type KRAS exon 2 tumors had an objective
response, compared with only 1.2% of patients with mutant KRAS
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wild-type KRAS exon 2 tumors [5]. Median OS was 9.5 and
4.8 months (P < 0.001), respectively, in patients with wild-type
KRAS codon 12/13 tumors treated with cetuximab plus BSC versus
BSC only whereas median OS was 4.5 and 4.6 months, respectively,
in patients with mutated KRAS tumors receiving cetuximab versus
BSC only (P = 0.89). The addition of cetuximab to BSC prolonged
median PFS in patients with wild-type KRAS compared with BSC
alone (3.7 versus 1.9 months, respectively; hazard ratio, 0.40;
95% CI, 0.30–0.54; P < 0.001) but not in patients with mutant
KRAS (1.8 months in both groups; hazard ratio, 0.99; 95% CI,
0.73–1.35; P = 0.96) [5]. The interaction between KRAS mutation
status and treatment effect was P = 0.01 for OS and P < 0.001 for
PFS.
Subsequently, a number of studies evaluating anti-EGFR mono-
clonal antibodies in mCRC were amended to focus on KRAS exon
2-selected populations, analyzed retrospectively to evaluate out-
comes in KRAS exon 2 wild-type patients, or designed to prospec-
tively enroll KRAS exon 2 wild-type patients [9,21–28]. These
studies compared the effect of adding cetuximab or panitumumab
to chemotherapy regimens with chemotherapy alone in ﬁrst-line
[21,22,24–27], second-line [23,28], or chemotherapy-refractory
[9] settings in patients with mCRC. In brief, these studies con-
ﬁrmed the validity of selection of patients with mCRC by KRAS
exon 2 mutation status. The addition of anti-EGFR monoclonal
antibody therapy to FOLFOX (oxaliplatin, 5-ﬂuorouracil, and leu-
covorin) or FOLFIRI (irinotecan, 5-ﬂuorouracil, and leucovorin)
was associated with improved outcomes in patients with
wild-type KRAS exon 2 tumors, but not in patients with KRAS exon
2 mutant tumors.
Based on these results, recommendations from the National
Comprehensive Cancer Network (NCCN) and the European
Society of Pathology strongly advised testing for KRAS gene muta-
tions in patients with mCRC and speciﬁed that the use of anti-EGFR
therapy in mCRC should be limited to patients with KRAS exon 2
wild-type tumors [29,30]. Moreover, prescribing information for
panitumumab and cetuximab were modiﬁed to limit their use to
patients with KRAS wild-type mCRC [31–34]. A companion diag-
nostic assay, the Therascreen KRAS RGQ PCR Kit (QIAGEN N.V.,
Venlo, Netherlands) that detects the presence of the seven most
frequent mutations in codons 12 and 13 was also approved by
the FDA to identify patients suitable for treatment with
panitumumab and cetuximab [35,36].EXON 2 EXON 3 EXON 4EXON 1KRAS
12 13 61 117 146
EXON 2 EXON 3 EXON 4EXON 1NRAS





Fig. 2. Relative distribution of KRAS exon 3 and 4 and NRAS exon 2, 3, and 4 in
patients with wild-type KRAS exon 2 tumors. Approximately 58% of patients have
KRAS exon 2 wild-type tumors. Incidence of mutations is from Sorich MJ, Wiese MD,
Rowland A, et al. Extended RAS mutations and anti-EGFR monoclonal antibody
survival beneﬁt in metastatic colorectal cancer: a meta-analysis of randomized
controlled trials. Ann Oncol. 2015;26(1):13–21.RAS mutations beyond KRAS exon 2 as predictors of response
Although it was clear that KRAS exon 2 (codon 12/13) testing
helped identify a patient population unlikely to beneﬁt from
anti-EGFR therapy, not all patients with wild-type KRAS exon 2
tumors responded to treatment with anti-EGFR therapy. Further
improvement in patient selection methods through the identiﬁca-
tion of additional predictive biomarkers could strengthen provision
of patient-speciﬁc therapy and help avoid unnecessary treatment
and treatment-related toxicity [37]. Given the evidence of consti-
tutively activating mutations in a broad array of loci in RAS family
genes (see above), it was suggested that RAS mutations beyond
KRAS exon 2 might also be predictive of lack of clinical beneﬁt with
anti-EGFR therapy in patients with mCRC.
Mutations in KRASwith potential predictive value beyond those
in codons 12/13 in exon 2 have been identiﬁed, particularly codon
61 in exon 3 and codon 146 in exon 4 [38]. The presence of these
KRAS mutations in patients with KRAS codons 12 and 13
wild-type disease, although rarer than codon 12/13 (exon 2) muta-
tions, was nevertheless associated with lack of response and
shorter PFS duration compared to patients with KRAS codon61/146 wild-type disease in small retrospective studies [38].
Mutations in NRAS exons 2, 3, and 4 (which are typically mutually
exclusive from mutations in KRAS) also occur in colorectal cancer
tumors [11]. The relative distribution of mutations in KRAS exon
3 and 4 and NRAS exons 2, 3, and 4 is shown in Fig. 2. Overall,
the incidence of RAS mutations has been found to be approxi-
mately 20% in patients with wild-type KRAS exon 2 tumors, with
a different distribution of mutations between exons in KRAS and
NRAS [39,40]. This incidence of RAS mutations beyond KRAS exon
2 suggested that, if such mutations had predictive value, a clini-
cally meaningful proportion of patients were exposed to potential
toxicity of anti-EGFR agents without the potential for clinical
beneﬁt.Extended RAS analysis in phase 2 and 3 studies
Early retrospective RAS analyses led to generation of the
hypothesis that these mutations beyond KRAS exon 2 might have
added additional predictive value for clinical outcomes [41–43].
In a retrospective analysis of the phase 3 study of single agent pan-
itumumab in patients with chemotherapy refractory disease the
hazard ratio for PFS improved to 0.38 (95% CI, 0.27–0.56) in the
RAS wild-type group from 0.45 (95% CI, 0.34–0.59) in the KRAS
exon 2 (codon 12/13) wild-type group [43]. The hazard ratio for
PFS in the RAS mutant group was 0.98 (95% CI, 0.73–1.31), com-
pared with a hazard ratio for PFS of 0.99 (95% CI, 0.73–1.36) in
the original KRAS mutant group [3].
Results from the extended RAS analyses of randomized phase 3
studies in patients with mCRC treated with chemotherapy and
anti-EGFR antibodies have provided the conﬁrmatory evidence
necessary to support reﬁnement of the appropriate patient popula-
tion by RAS mutation status. A summary of PFS and OS outcomes
by KRAS exon 2 and RAS mutational status in key studies of
panitumumab and cetuximab plus chemotherapy in mCRC is
presented in Table 1.
The primary ﬁndings from a randomized study (PRIME) assess-
ing the efﬁcacy of ﬁrst-line panitumumab plus FOLFOX versus
FOLFOX alone showed, consistent with other studies, that KRAS
exon 2 mutations were a predictor of lack of response to panitu-
mumab in patients with mCRC [44]. In the study’s primary analysis
– which evaluated outcomes in the KRAS exon 2 wild-type
population (RAS ascertainment, 90%), panitumumab signiﬁcantly
improved PFS (9.6 versus 8.0 months; hazard ratio, 0.80; 95% CI,
0.66–0.97; P = 0.02) and there was a trend toward improvement
in overall survival (23.9 versus 19.7 months; hazard ratio, 0.83;
95% CI, 0.67–1.02; P = 0.072), although this was not signiﬁcant. In
a subsequent prospective-retrospective analysis (ie, the analysis
plan was prespeciﬁed before the RAS testing but was performed
after the primary analysis by KRAS), the treatment effect of
panitumumab was evaluated by RAS mutations which include
those from KRAS and NRAS exons 2, 3, and 4. In these patients
Table 1
Summary of PFS and OS outcomes by KRAS exon 2 and RAS mutational status in key studies of panitumumab and cetuximab in patients with metastatic colorectal cancer.
KRAS exon 2 wild-type Extended RAS ascertainment RAS wild-type
PRIME [44] (Panitumumab + FOLFOX4 vs FOLFOX4)
PFS, HR (95% CI) 0.80 (0.66–0.97) 90% 0.72 (0.58–0.90)
P 0.02 0.004
OS*, HR (95% CI) 0.83 (0.67–1.02) 0.78 (0.62–0.99)
P 0.07 0.04
Study 20050181 [23,50] (Panitumumab + FOLFIRI vs FOLFIRI)
PFS, HR (95% CI) 0.73 (0.59–0.90) 85% 0.70 (0.54–0.91)
P 0.004 0.007
OS, HR (95% CI) 0.85 (0.70–1.04) 0.81 (0.63–1.03)
P 0.12 0.08
PEAK [45] (Panitumumab + mFOLFOX6 vs Bevacizumab + mFOLFOX6)
PFS, HR (95% CI) 0.87 (0.65–1.17) 82% 0.65 (0.44–0.96)
P 0.353 0.029
OS, HR (95% CI) 0.62 (0.44–0.89) 0.63 (0.39–1.02)
P 0.009 0.058
OPUS [26,47] (Cetuximab + FOLFOX4 vs FOLFOX4)
PFS, HR (95% CI) 0.57 (0.38–0.86) 75% 0.53 (0.27–1.04)
P 0.0064 0.062
OS, HR (95% CI) 0.86 (0.60–1.22) 0.94 (0.56–1.56)
P 0.39 0.80
CRYSTAL [46] (Cetuximab + FOLFIRI vs FOLFIRI)
PFS, HR (95% CI) 0.70 (0.56–0.87) 69% 0.56 (0.41–0.76)
P 0.0012 0.0002
OS, HR (95% CI) 0.80 (0.67–0.95) 0.69 (0.54–0.88)
P 0.0093 0.0024
FIRE-3 [27] (Cetuximab + FOLFIRI vs Bevacizumab + FOLFIRI)
PFS, HR (95% CI) 1.06 (0.88–1.26) 69% 0.93 (0.74–1.17)
P 0.55 0.54
OS, HR (95% CI) 0.77 (0.62–0.96) 0.70 (0.53–0.92)
P 0.017 0.01
CALGB/SWOG 80405 [49] (Cetuximab + FOLFIRI or FOLFOX vs Bevacizumab + FOLFIRI or FOLFOX)
PFS, HR (95% CI) 1.04 (0.91–1.17) 55% 1.1 (0.9–1.3)
P 0.55 0.31
OS, HR (95% CI) 0.92 (0.78–1.09) 0.9 (0.7–1.1)
P 0.34 0.40
CRYSTAL = cetuximab combined with irinotecan in ﬁrst-line therapy for metastatic colorectal cancer; FOLFIRI = ﬂuorouracil, folinic acid, and irinotecan;
FOLFOX4 = ﬂuorouracil, leucovorin, and oxaliplatin; KRAS = the Kirsten rat sarcoma-2 virus oncogene; HR = hazard ratio; mCRC = metastatic colorectal cancer;
mFOLFOX6 = modiﬁed ﬂuorouracil, leucovorin, and oxaliplatin; MT = mutant type; NA = not available; NRAS = neuroblastoma RAS viral oncogene homolog; OS = overall
survival; PEAK = panitumumab efﬁcacy in combination with modiﬁed ﬂuorouracil, leucovorin, and oxaliplatin (mFOLFOX6) against bevacizumab plus mFOLFOX6 in mCRC
subjects with wild-type KRAS tumors; PFS = progression-free survival; PRIME = panitumumab randomized trial in combination with chemotherapy for metastatic colorectal
cancer to determine efﬁcacy; RAS = rat sarcoma-2 virus oncogene; WT = wild type.
* Primary analysis. With the exception of Study 20050181 (second-line treatment), all studies were ﬁrst-line treatment.
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FOLFOX4 versus FOLFOX4 alone was associated with signiﬁcant
improvements in PFS (10.1 versus 7.9 months; hazard ratio, 0.72;
95% CI, 0.58–0.90; P = 0.004) and OS (26.0 versus 20.2 months;
hazard ratio, 0.78; 95% CI, 0.62–0.99; P = 0.04) [44]. In patients
with wild-type KRAS exon 2 tumors but with other RAS mutations,
panitumumab plus FOLFOX4 did not improve PFS (hazard ratio,
1.28; 95% CI, 0.79–2.07; P = 0.33) or OS (hazard ratio, 1.29; 95%
CI, 0.79–2.10; P = 0.31). The results of interaction testing for the
comparison of outcomes in these patients with those with RAS
wild-type tumors was P = 0.04 for PFS and P = 0.07 for OS. These
data represented the ﬁrst demonstration in a phase 3 study (albeit
a prospective-retrospective analysis) of the value of extended RAS
analysis for anti-EGFR therapy.
RAS status was prospectively evaluated in PEAK, a randomized
phase 2 study of panitumumab plus modiﬁed (m)FOLFOX6 versus
bevacizumab plus mFOLFOX6 [45]. Eighty-two percent of patients
who underwent extended RAS analysis had KRAS or RAS status [45].
In a prespeciﬁed extended RAS analysis, RAS mutations beyond
KRAS exon 2 appeared to be predictive for the treatment effect of
panitumumab on OS.
Results from retrospective analyses of studies evaluating treat-
ment outcome with cetuximab in the ﬁrst-line setting according toRASmutational status have provided further data supporting valid-
ity of extended RAS analysis. The CRYSTAL study randomly
assigned 1198 patients with EGFR-positive mCRC to cetuximab
plus FOLFIRI or FOLFIRI alone [24]. When treatment outcomes
were analyzed according to RAS mutation status, KRAS and NRAS
mutational status was conﬁrmed to be strongly predictive for the
efﬁcacy of cetuximab plus FOLFIRI: mutations in KRAS and NRAS
were associated with lack of clinical beneﬁt with the addition of
cetuximab to FOLFIRI [46].
Similarly, in the OPUS study of cetuximab plus FOLFOX4 versus
FOLFOX4 alone, when KRAS exon 2 wild-type tumors were
screened for additional RASmutations, the presence of any activat-
ing RAS mutation was predictive of lack of beneﬁt from the addi-
tion of cetuximab [26,47]. When the effects of mutations within
KRAS and NRAS; exon 2, 3, and 4; BRAF V600E; PIK3CA; exon 9
and 20; and AKT were examined in patients in the FIRE-3 study
of cetuximab plus FOLFIRI versus FOLFIRI alone, the exclusion of
patients with any RASmutation was predictive of improved beneﬁt
from cetuximab [48].
Results from a retrospective extended RAS analysis of the
CALGB/SWOG 80405 study were recently reported [49]. The study
randomized patients with wild-type KRAS exon 2 mCRC to receive
either cetuximab or bevacizumab plus chemotherapy (FOLFOX or
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ratio for OS was 0.92 (0.78–1.09; P = 0.34) for cetuximab versus
bevacizumab. At the time of presentation, 55% of patients with
KRAS exon 2 wild-type tumors were evaluable for additional muta-
tions in KRAS and NRAS status and, among this RAS-evaluable
group, the hazard ratio for OS was 0.9 (0.8–1.1; P = 0.49). Among
patients with RAS wild-type tumors, the hazard ratio for OS was
0.9 (0.7–1.1; P = 0.40) and therefore, selection of patients using
extended RAS analysis did not improve outcomes. Deﬁnitive
conclusions from this study will require maturation of the data
with increased sample ascertainment for extended RAS analysis,
evaluation of subsequent treatments, and distribution of RAS
mutations across arms.
In the second-line setting, improvements in predictive value
were reported in a prospective-retrospective study evaluating
RAS mutations in patients receiving panitumumab plus FOLFIRI
versus FOLFIRI alone (the 20050181 study) [50]. A total of 18% of
patients with wild-type KRAS exon 2 tumors had additional RAS
mutations (KRAS exons 3, and 4; NRAS exons 2, 3, and 4) [50].
Patients with mutated RAS tumors were unlikely to beneﬁt from
panitumumab, similar to the ﬁndings in patients with KRAS exon
2 mutations. BRAF mutations in the absence of RAS mutations
appeared to be associated with poorer OS regardless of treatment
arm [50].
A systematic review and meta-analysis of nine randomized con-
trolled trials of anti-EGFR therapies for mCRC that assessed the
predictive value of RASmutations beyond KRAS exon 2 has recently
been published [39]. Collectively, the available data supported the
value of extended RAS analysis to guide treatment decisions for
anti-EGFR therapy and challenges the ability of KRAS exon 2
biomarker testing to adequately identify those patients with
mCRC most likely to beneﬁt from anti-EGFR therapy and to protect
patients unlikely to respond from unnecessary treatment-related
toxicity [39]. Approximately 20% of the 5948 patients with
wild-type KRAS exon 2 tumors evaluated in the studies had at least
one RAS mutation other than KRAS exon 2 (KRAS exon 3 or 4 or
NRAS 2, 3, or 4). The meta-analysis found that panitumumab and
cetuximab both signiﬁcantly improved hazard ratios for PFS
(0.60; 95% CI, 0.48–0.76; P < 0.001), OS (0.72; 95% CI, 0.56–0.92;
P = 0.008), and treatment effect on response rate (odds ratio,
3.71; 95% CI, 2.16–6.36) in patients with RAS wild-type tumors
compared with those patients with any new RAS mutation.
Meanwhile, there was no difference in PFS or OS beneﬁt between
patients with tumors with KRAS exon 2 mutations and those with
other RASmutations. The results were found to be consistent inde-
pendent of anti-EGFR agent, lines of therapy, and concomitant
chemotherapy agent [39]. It is also important to note that a variety
of different analytical techniques were used to evaluate RAS
mutational status in these studies, including bidirectional Sanger
sequencing/WAVE-based sequencing [44,45,50], BEAMing [46,47],
and pyrosequencing [48], but that this did not inﬂuence the predic-
tive value for RAS mutations.Acquisition of RAS mutations as a mechanism of resistance
Some patients develop RAS mutations during therapy with
anti-EGFR monoclonal antibodies [51–53]. For example, among 24
KRASwild-type patients who received treatment with panitumumab,
9 developed KRAS mutations during therapy, typically within
6 months of initiation of therapy [52]. Development of such
mutations during therapy may be a result of expansion of
KRAS-mutant subclones present before initiation of therapy and
may represent a potential mechanism of resistance to anti-EGFR
therapy [52]. Preclinical studies have suggested that combined
anti-EGFR and MEK inhibition might overcome such resistance[54], and this hypothesis is being evaluated in ongoing clinical
studies (ClinicalTrials gov identiﬁer, NCT01750918).Prognostic/predictive value of BRAF mutations
It is clear that a BRAF mutation is prognostic of a poor outcome
irrespective of treatment [44,50,55–57]. In the PRIME study, for
instance, median OS among patients with BRAF mutations in the
FOLFOX arm was 9.2 months compared with 20.9 months among
patients without either RAS or BRAFmutations. Whether mutations
in BRAF might also have predictive value, however, has been con-
troversial. While some studies have suggested that patients with
BRAFmutations may be less likely to respond to anti-EGFR therapy
[41,58] others have not. In the open-label phase 3 study of
panitumumab plus BSC compared to BSC alone, the hazard ratio
for PFS was 0.34 in patients with BRAF-mutant tumors and 0.37
in patients with BRAF wild-type tumors [42]. In the PRIME study,
the presence of BRAF mutations did not appear to be associated
with lack of treatment effect to panitumumab [44]. Similarly,
BRAF mutations were not predictive for the treatment effect of
cetuximab in the CRYSTAL study, but were associated with poor
prognosis [59]. Careful consideration should be given to
enrollment of patients with BRAFmutant tumors into clinical trials
to address this high unmet need. It is encouraging to note that
early phase prospective studies are currently evaluating novel
treatment combinations of anti-EGFR monoclonal antibodies
and BRAF inhibitors in patients with BRAF mutant mCRC
(ClinicalTrials gov identiﬁers, NCT02164916; NCT01750918).Discussion
It has become clear from emerging data that KRAS exon 2
(codon 12/13) mutation status alone is not sufﬁcient to fully
explain heterogeneity of treatment response to anti-EGFR therapy
in mCRC, and that molecular testing for biomarkers beyond KRAS
codons 12 and 13 has additional predictive value. There is now
strong evidence that extended RAS analysis (KRAS exons 2, 3, and
4 and NRAS exons 2, 3, and 4) is appropriate to enhance identiﬁca-
tion of patients most likely to beneﬁt from anti-EGFR monoclonal
antibody therapy and to avoid treatment unlikely to be of value
to the patient and with the potential for treatment-related toxicity.
Although there has been evaluation of other potential predictive
biomarkers for anti-EGFR therapy in patients with mCRC (includ-
ing EGFR ligands [60,61], PTEN [42,62,63], PIK3CA [42,62,64], and,
most notably, BRAF [42,44,62]), RAS mutations represent the only
clinically validated biomarkers.
These ﬁndings are now being incorporated into the latest clini-
cal practice guidelines. The European Society for Medical Oncology
(ESMO), NCCN, the European Society of Pathology, and the
Association of Clinical Pathologists Molecular Pathology and
Diagnostics Group in the United Kingdom now strongly recom-
mend determination of KRAS/NRAS gene status prior to the initia-
tion of treatment, including whenever possible non-KRAS exon 2
mutation status, of tumor tissue in patients with mCRC
[29,30,65,66]; the American Society for Clinical Pathology,
College of American Pathologists, and Association for Molecular
Pathology are currently developing revised guidelines. The
European Medicines Agency’s summaries of product characteris-
tics for cetuximab and panitumumab require evidence of
wild-type RAS (KRAS/NRAS) status before treatment [67,68].
However, barriers to widespread clinical use remain and it is
unclear how many eligible patient tumors are undergoing
extended RAS analysis. The difference between KRAS exon 2 testing
(‘‘KRAS’’) and extended RAS analysis (‘‘RAS’’) is not yet widely rec-
ognized by oncologists and pathologists. The FDA-approved
658 J.R. Hecht et al. / Cancer Treatment Reviews 41 (2015) 653–659TheraScreen assay only evaluates mutations in KRAS exon 2
(codons 12/13) [35,36]. There is currently no standardized
extended RAS testing and the large studies described above used
a variety of methods including bidirectional Sanger sequencing
and WAVE-based Surveyor Scan Kits (PRIME) [44], pyrosequencing
(FIRE-3) [27], and BEAMing (CRYSTAL) [46]. Other groups have
employed targeted multigene next-generation sequencing panels
[42], and some are even performing whole exome analysis [69].
While the fraction of patients with non-exon 2 KRAS and NRAS
mutations appears similar between studies, the sensitivity, neo-
plastic cell content and cut-offs for mutation calling vary. It is
unknown whether these analytical methods yield clinically signif-
icant differences. Analyses performed to date have used relatively
conservative neoplastic cell content and mutant DNA sensitivity
levels of 5% to 10%, but some recent evidence has suggested that
lower levels of RAS mutation might also predict poor response to
anti-EGFR therapy [70]. Such analyses will require closer attention
to microdissection of tissue to account for the high variability of
stromal inﬁltrates, and harmonization of methods for
meta-analyses.
Conclusion
The discovery that extended RAS analysis identiﬁes a group of
patients with advanced colorectal cancer who do not beneﬁt from
anti-EGFR therapy has changed the practice of oncology and has
the potential to spare patients from exposure to ineffective ther-
apy. In the near future, it is important for the oncology community
to validate extended RAS analysis assays and make certain that
patients who are candidates for anti-EGFR therapy undergo appro-
priate testing and treatment.
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